tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Eliana Merle, 91 are a BUY (78.45%), 25 are a HOLD (21.55%).
Analyst Eliana Merle, currently employed at UBS, carries an average stock price target met ratio of 46.19% that have a potential upside of 42.1% achieved within 195 days.
Eliana Merle’s has documented 243 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 20-Feb-2025.
Analyst best performing recommendations are on ZNTL (ZENTALIS PHARMACEUTICALS LLC).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) at 11/7/2019. The price target of $28 was fulfilled within 1 day with a profit of $8.16 (22.57%) receiving and performance score of 225.66.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$54
$29.86 (123.70%)
$57
23 days ago
(04-Mar-2025)
12/21 (57.14%)
$28.85 (114.71%)
382
Hold
$29
$4.86 (20.13%)
$30
23 days ago
(04-Mar-2025)
16/20 (80%)
$3.85 (15.31%)
136
Hold
$25
$0.86 (3.56%)
$26
23 days ago
(04-Mar-2025)
5/5 (100%)
$-0.15 (-0.60%)
42
Hold
$32
$7.86 (32.56%)
$36
23 days ago
(04-Mar-2025)
1/10 (10%)
$6.85 (27.24%)
24
Buy
$57
$32.86 (136.12%)
$57
23 days ago
(04-Mar-2025)
3/22 (13.64%)
$31.85 (126.64%)
108
Which stock is Eliana Merle is most bullish on?
Which stock is Eliana Merle is most reserved on?
What Year was the first public recommendation made by Eliana Merle?
